Introduction
The ability to store nutrients is vital to survival for all organisms in periods of acute or prolonged shortage of nutrient supply. In mammals, the liver is a major organ responsible for maintaining both short-term and long-term whole-body energy needs by its capacity to induce a number of changes in terms of stored and released energy in the body under widely changing physiological conditions. Alterations in energy intake induce a number of metabolic and hormonal changes in the body. The liver functions as a mediator between dietary, as well as endogenous, sources of energy and the extrahepatic organs that continuously need energy, primarily the brain.
Metabolically, the liver is the most versatile organ of the whole body with a metabolism cycling daily between the fed and fasted states. In the fed (anabolic) state, digestion yields simple sugars that are converted to pyruvate (via glycolysis), which is either oxidized to provide energy or channelled into pathways for synthesis of fatty acids (via lipogenesis) for storage. Excess glucose is also stored as glycogen (the total hepatic glucose store is only sufficient for a few hours use), providing a short-term source of carbohydrates for emergency use. The coordinated regulation of these processes allows for efficient utilization of dietary carbohydrate. Hepatic fuel metabolism changes considerably under the different nutritional situations. In the fasted (catabolic) state, the liver becomes a glucose producer (breakdown of stored hepatic glycogen and synthesis of glucose from lactate, amino acids, glycerol, and pyruvate), lipogenesis is slowed down, and fatty acid oxidation and ketogenesis are activated to supply energy and metabolic fuels for extrahepatic organs. Because the liver is the metabolic factory of the body, alterations in liver function clearly affect whole-body metabolism and energy homeostasis and underlie the development of metabolic diseases, including type 2 diabetes and the metabolic syndrome. Hence, understanding the mechanisms regulating hepatic energy metabolism is a prerequisite for developing new pharmacological strategies aimed at treating these metabolic diseases.
Over the last few years, a growing body of evidence indicates that AMP-activated protein kinase (AMPK), a serine threonine kinase comprising a catalytic subunit and regulatory and subunits, represents a point of convergence of regulatory signals monitoring α β γ systemic and cellular energy status. AMPK functions as a fuel sensor in most tissues and organs, including liver, skeletal muscle, heart, hypothalamus and adipose tissue, where it inhibits anabolic pathways and stimulates catabolic pathways in response to limited energy availability, thus simultaneously sparing limited energy resources and acquiring extra energy. AMPK acts first by directly affecting enzymes activities, involved in carbohydrate, lipid and protein biosynthesis, and second by longer-term transcriptional control of key players of these metabolic pathways. AMPK emerges as a major regulator of glucose and lipid metabolism and represents an attractive target for therapeutic intervention in the treatment of hepatic disorders. Important progress has recently been made in the comprehension of the pathophysiological role of AMPK in hepatic energy metabolism and this review provides a general overview of AMPK regulation, its activators and its functions in the liver.
Structure and regulation of AMPK in the liver
AMPK exists as a heterotrimeric complex consisting of a catalytic subunit and two regulatory subunits and involved in best of our knowledge, no selective association between catalytic 1 and 2 and regulatory and subunits or differences in the activity of α α β γ the various hepatic AMPK complexes combination have been reported. Nevertheless, it should be noted that AMPK complexes distribution can be regulated intracellularly with AMPK 2-containing complexes present in both nucleus and cytoplasm raising the α possibility of direct regulation of gene transcription ( ) and with AMPK 1-containing complexes localized in the cytoplasm Salt et al., 1998 α but also at the plasma membrane ( , ) . Changes in the subcellular localization of AMPK 2 in Evans et al., 2005 Hallows et al., 2003 response to specific stimuli appear to be conserved from yeast to mammals via a mechanism involving the interaction with the regulatory β subunits ( , ). In mammalian muscle cells, AMPK 2 bound to the 2 subunit translocates to the Suzuki et al., 2007 Vincent et al., 2001 α β nucleus in a manner dependent on a nuclear localization signal that is present in AMPK 2 but not in AMPK 1 subunit. AMPK 2 bound to α α α the 1 subunit is anchored into the cytoplasm at the outer mitochondrial membrane through the myristoylation of 1 subunit. These data β β suggest that activation of AMPK complexes may elicit distinct metabolic effects in tissues and cells depending on the expression of the different -and -subunit isoforms and illustrate the complexity of the molecular mechanisms by which energy metabolism can be α β regulated by AMPK.
Regulation of AMPK activity involves both direct allosteric activation and reversible phosphorylation. Activation of AMPK requires phosphorylation on Thr-172 within the catalytic subunit and three upstream kinases have been identified corresponding to the tumor suppressor LKB1 kinase, CaMKK (C 2 /calmodulin-dependent protein kinase kinase ) and possibly TAK1 (TGF -activated kinase-1, a β α + β β member of the mitogen-activated protein kinase kinase family). LKB1 is mainly involved in Thr-172 phosphorylation following change in AMP:ATP ratio (  ,  ,  ) . It has become evident in the last years that LKB1 plays a Hawley et al., 2003 Shaw et al., 2004 Woods et al., 2003 crucial role in activating AMPK to control glucose and lipid metabolism in the liver ( , ). It has been Shaw et al., 2005 Imai et al., 2006 suggested that LKB1 may be constitutively active ( , ) but recent studies indicates that cytosolic Lizcano et al., 2004 Sakamoto et al., 2004 localization and activity of LKB1 can be governed by LKB1 acetylation status in the liver ( ). CaMKK is viewed as an Lan et al., 2008 β alternate upstream kinase that could also phosphorylate Thr-172 and activate AMPK in intact cells by an AMP-independent manner in response to increased intracellular Ca concentrations ( , , ) . However, CaMKK the kinase domain that protects AMPK from dephosphorylation of Thr-172 ( ), probably catalysed by a form of protein Riek et al., 2008 phosphatase-2C ( ). The combination of the allosteric and phosphorylation effects causes >1000-fold increase in kinase Sanders et al., 2007 activity ( ) allowing to respond to small changes in cellular energy status in a highly sensitive manner. Suter et al., 2006 Activators of AMPK in the liver AMPK is activated in response to a variety of metabolic stresses that typically, but not exclusively, change the cellular AMP:ATP ratio, either by increasing ATP consumption (activation of biosynthetic pathways) or reducing ATP production following hypoxia, glucose deprivation and inhibition of mitochondrial oxidative phosphorylation with metabolic poisons (arsenite, oligomycin, dinitrophenol, azide and antimycin A) ( ). AMPK plays a central role in the metabolic adaptation to acute and chronic nutritional Towler and Hardie, 2007 stresses. For instance, AMPK is activated in the liver by the metabolic challenges imposed by either a 24-h fast ( , Munday et al., 1991 ) and dietary energy restriction ( ). However, in other studies, fasting and caloric restriction did not Witters et al., 1994 Jiang et al., 2008 activate liver AMPK ( , ). Interestingly, it has been noted that the metabolic demands during muscular Gonzalez et al., To et al., 2007 work results in a decrease in energy status of the liver ( ). Indeed, increased AMPK activation has been demonstrated Camacho et al., 2006 following short-term exercise in rat liver ( , ) . Long-term exercise also induced significant Winder, 1999 Park et al., 2002 increase in AMPK phosphorylation as well as AMPK 1-and 2-subunit mRNA levels in the liver, suggesting a role for hepatic AMPK in α α long-term exercise-induced hepatic adaptations ( ). Takekoshi et al., 2006 In the liver, the transition from the fasted to the fed state is also associated with physiological changes in energy dynamics. The reversal of the metabolic response to starvation includes alterations in enzyme phosphorylation states and changes in the concentration of key regulatory molecules. It has been reported that AMPK coordinates the changes in the activity and/or expression of a number of enzymes of lipid metabolism during refeeding ( , Munday et al., 1991 Gonzalez et al., 2004 Assifi et al., 2005 Dentin et al., 2005 Refeeding causes a 40 decrease in the activity of AMPK 1 within 1 h, with additional decrease in both AMPK 1 and AMPK 2 % α α α activities occurring between 1 and 24 h ( ). It is noteworthy that LKB1 activity could also be modulated during the Assifi et al., 2005 starvation-refeeding transition in association with its acetylation and intracellular localization ( ). The modification of Lan et al., 2008 AMPK activity during the starved-fed transition is compatible with earlier studies that linked these changes to increase in plasma insulin [ reported to decrease AMPK activity in isolated hepatocytes ( ) , and decrease in glucagon showed to activate Witters and Kemp, 1992 ] [ hepatic AMPK ( ) , possibly by a protein kinase A-induced phosphorylation and activation of LKB1 ( Sim and Hardie, 1988 ] Kimball et al.,
). In addition, changes in circulating levels of various hormones and adipokines during refeeding, may directly affect AMPK activity 2004 in the hepatocytes and could also contribute to the fasted-to-fed transition from catabolism to anabolism in the liver. It has been reported that hepatic AMPK can be regulated by ghrelin ( , ), endocannabinoids ( ), Barazzoni et al., 2005 Kola et Corton et al., 1995 Cool et al., ) , polyphenols ( ) and two major classes of existing antidiabetic drugs biguanides (metformin and phenformin) ( Zang et al., 2006 ) and thiazolidinediones (TZDs) ( ). Zhou et al., 2001 Saha et al., 2004 AICAR is a cell-permeable nucleoside which could be metabolically converted to 5-aminoimidazole-4-carboxamide ribotide (AICA Importantly, AMPK-independent effects of AICAR in the control of hepatic glucose uptake ( ), phosphatidylcholine Guigas et al., 2006 synthesis ( ) and autophagic proteolysis ( ) probably associated with its effect on ATP depletion where Jacobs et al., 2007 Meley et al., 2006 also recently reported. Detrimental effect of AICAR is likely to be due to an AMPK-independent inhibition of mitochondrial oxidative phosphorylation induced by a concomitant effect of ZMP on the mitochondrial respiratory chain complex 1 and a drop of adenine nucleotides and inorganic phosphate following its phosphorylation ( ). Furthermore, we established that ZTP Guigas et al., 2007 accumulation induced uncoupling of mitochondrial oxidative phosphorylation, an effect that could worsen the change in cellular energetic by decreasing the yield of ATP synthesis (
). In addition, it should be noted another important caveat in the use of Guigas et al., 2007 AICAR because ZMP accumulation does affect certain other AMP-regulated enzymes such as glucokinase and fructose 1,6-bisphosphatase causing inhibition of glycolysis and gluconeogenesis in hepatocytes ( , ). Vincent et al., 1992 Vincent et al., 1991 Therefore, like all pharmacological approaches, results of experiments using AICAR must be interpreted with caution and it remains to be clearly determined whether all AICAR effects described are mediated by AMPK. In addition, it has been demonstrated that uptake of AICAR into cells, mediated by the adenosine transport system, is blocked by a number of protein kinase inhibitors, thus preventing ZMP accumulation and subsequent AMPK activation ( , ).
Fryer et al., 2002 Guigas, unpublished results
Recently, a new class of AMPK activators have been identified after the screening of a chemical library using partially purified AMPK from rat liver. The non nucleoside thienopyridone A-592017 emerged from the initial screen, and after optimization the more potent one, A-769662, was developed. Specificity of this new compound has been tested on a panel of 76 protein kinases and the majority of kinases were not significantly affected at 10 M ( ) suggesting that A-769662 is a new specific activator of AMPK. Unlike Baur et al., 2006 Collins et al., 2007 Zang et al., 2006 polyphenols are mediated by their ability to activate sirtuin 1 (SIRT1), a mammalian ortholog of Sir2 (silent information regulator 2), an NAD-dependent deacetylase that acts as a master metabolic sensor of NAD and modulates cellular metabolism and life span (
). It has been demonstrated that SIRT1 activation by resveratrol functions as an upstream regulator in the LKB1/AMPK signaling 2006 axis ( ). The ability of resveratrol to stimulate AMPK was mimicked by overexpression of SIRT1 and abolished by Hou et al., 2008 knockdown or pharmacological inhibition of SIRT1. Furthermore, AMPK activation by resveratrol-activated SIRT1 is mediated by the upstream kinase, LKB1, but not CaMKK . The mechanism by which SIRT1 activation by polyphenols leads to LKB1-dependent AMPK β activation relies on the direct deacetylation of LKB1 by SIRT1 ( ). Indeed, activation of SIRT1 deacetylates LKB1, which Lan et al., 2008 in turn increases its cytoplasmic localization, its association with the LKB1 activator STRAD and its ability to activate AMPK.
Nevertheless, it should be noted that AMPK activation by polyphenols may involve distinct regulators. It has been shown that the EGCG-induced increase in AMPK phosphorylation is mediated by CaMKK activation through production of ROS ( ). Collins et al., 2007 Furthermore, the SIRT1 regulation of LKB1/AMPK signaling appears to be tissue-specific as resveratrol-stimulated AMPK activation in neurons was independent of SIRT1 ( ). Dasgupta and Milbrandt, 2007 The molecular pathway of AMPK activation by the antidiabetic drug metformin has been unclear ( ) but the direct Zhou et al., 2001 inhibition of the respiratory chain complex 1 by the biguanide constitutes the more convincing molecular mechanism, thus, leading to reduced cellular ATP and increased AMP ( , , ) . This is supported by the fact El-Mir et al., Brunmair et al., 2004 Owen et al., 2000 that metformin treatment in primary hepatocytes resulted in a decrease in ATP content ( ). It should be noted that Guigas et al., 2006 metformin could also exert AMPK-independent effects in the liver, probably due to its effect on cellular ATP levels ( ). Guigas et al., 2006 It has been reported that TZDs acutely activate AMPK by a mechanism independent of PPAR -regulated gene transcription, which γ appears to be associated with change in cellular energy state and could potentially increase AMPK activity ( , Brunmair et al., 2004 Saha et ). al., 2004 Regulation of hepatic lipid metabolism AMPK phosphorylates and inactivates a number of metabolic enzymes involved in lipid metabolism in order to maintain liver energy status. AMPK coordinates the changes in the hepatic lipid metabolism and, so, regulates the partitioning of fatty acids between oxidative and biosynthetic pathways. 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) and acetyl CoA carboxylase (ACC), key enzymes in cholesterol and fatty acid synthesis respectively, were the first enzymes shown to be phosphorylated and inactivated by AMPK ( , ) . Although the action of AMPK is achieved by rapid and direct Corton et al., 1994 Henin et al., 1995 phosphorylation of these enzymes, long-term effects have also been clearly demonstrated on gene expression. AMPK activation by AICAR or by the use of adenovirus-mediated overexpression of a constitutively active form of the 2 catalytic subunit (AMPK 2-CA) α α inhibits glycolytic and lipogenic gene expression ( , , , , Foretz et al., 2005 Leclerc et al., 2001 Woods et al., 2000 Foretz et al., 1998 ), preserving glucose for ATP-producing pathways rather than for lipid synthesis. Of note, AMPK activation reduces Leclerc et al., 1998 expression of sterol regulatory element-binding protein-1c (SREBP1c) AMPK directly phosphorylates ChREBP and modulates its DNA binding activity ( ). Polyunsaturated fatty acids Kawaguchi et al., 2002 (PUFAs) expression indicating the existence of AMPK-independent mechanism(s) ( ). Viollet et al., 2006 In the cholesterol synthesis pathway, AMPK blocks the conversion of HMG-CoA to mevalonate. One could expect detrimental effect on cholesterol homeostasis when AMPK activity is altered. In total and liver-specific AMPK 2 KO mice, plasma levels for total and HDL α cholesterol are not statistically different compared to controls but have a tendency to be higher ( , Andreelli et al., Viollet et al., 2003 ). This suggested that remaining 1 subunit activity in AMPK 2 KO mice is sufficient to control hepatic cholesterol synthesis and that α α HMG-CoA reductase is a target for both catalytic isoforms of AMPK.
ACC is an important rate-controlling enzyme for the synthesis of malonyl-CoA, which is both a critical precursor for biosynthesis of fatty acids and a potent inhibitor of mitochondrial fatty acid oxidation via the allosteric regulation of carnitine palmitoyltransferase-1 (CPT-1) which catalyzes the entry of long-chain fatty acyl-CoA into mitochondria. Inhibition of ACC by AMPK leads to a fall in malonyl-CoA content and a subsequent decrease in fatty acid synthesis concomitantly with an increase in -oxidation ( , 
Regulation of hepatic mitochondrial biogenesis and function
As reported recently, AMPK has been also involved in the control of mitochondrial biogenesis in the liver, a role already evidenced in skeletal muscles ( ). 
Regulation of hepatic glucose production
Recent results from various animal models confirm the physiological importance of hepatic AMPK for whole-body glucose homeostasis. It has been first shown that systemic infusion of AICAR in normal and insulin-resistant obese rats leads to the inhibition of hepatic glucose production (HGP) ( ). Then, several studies reported that AICAR treatment improve blood glucose Bergeron et al., 2001 levels and glucose tolerance in animal models of type 2 diabetes. However, the relative roles played by skeletal muscle and liver in mediating the hypoglycemic effect of AICAR remain unclear. In muscle-specific AMPK dominant-negative mice, AICAR has a weaker hypoglycemic effect than in control animals ( ), suggesting that this compound lowers glycemia at least partly by increasing Mu et al., 2001 muscle glucose uptake. We demonstrated that AMPK 1 2 / mice display an impaired hypoglycemic response to AICAR, indicating
that the liver as well participate to the hypoglycemic effect of AICAR ( ). It has been also reported that short-term hepatic Dusp4 act sequentially to mediate the inhibitory effect of AMPK on hepatic gluconeogenesis: increase in Egr1 protein is accompanied with increased binding to the Dusp4 promoter leading to Dusp4 expression and inhibition of PEPCK and G6Pase gene transcription ( ). Berasi et al., 2006 The importance of AMPK in the control of glucose output by the liver was recently highlighted by the potent effects of circulating adipocyte-derived hormones on whole-body glucose metabolism. A physiological link has been established between circulating resistin levels and hepatic AMPK activity in the maintenance of blood glucose ( ). Low blood glucose levels and reduced Banerjee et al., 2004 HGP in mice lacking resistin are likely related, at least in part, to activation of AMPK and decreased expression of gluconeogenic enzymes in the liver. Interestingly, adiponectin signaling opposes that of resistin in the control of glucose homeostasis and activation of AMPK is though to underlie the ability of this adipocyte hormone to reduce HGP ( ). According to this result, adiponectin Yamauchi et al., 2002 failed to regulate HGP in liver-specific AMPK 2 KO mice ( ). AdipoR1 and AdipoR2 serve as adiponectin receptors AMPK was also found to phosphorylate TORC2 and regulate cytoplasmic translocation of TORC2 in primary hepatocyte cultures (Koo et ). Interestingly, in the absence of LKB1 in the liver, the expression of some of the key gluconeogenic genes are enhanced and the al., 2005
antidiabetic drug metformin no longer reduced blood glucose levels, demonstrating that hepatic LKB1/AMPK axis is required to maintain blood glucose levels ( ). LKB1 phosphorylates and activates a number of kinases including AMPK and SIK family Shaw et al., 2005 members ( ), suggesting that genetic deletion of LKB1 in liver will result in the loss of multiple metabolic checkpoints Lizcano et al., 2004 in the regulation of TORC2. In LKB1-deficient liver, AMPK was almost completely inactive, TORC2 was predominantly nuclear and fasting blood glucose levels were highly increased concomitantly with PEPCK and G6Pase gene expression ( ). The Shaw et al., 2005 reduction of TORC2 protein levels by injection of adenoviruses bearing small hairpin RNA for TORC2 in mice lacking LKB1 in the liver resulted in decreased PGC-1 protein levels accompanied by a significant decrease in fasting blood glucose levels, suggesting that TORC2 α is a critical downstream target of LKB1-dependent kinases in the control of gluconeogenesis ( ). In addition, a recent Shaw et al., 2005 study has shown that metformin regulates hepatic gluconeogenesis through AMPK-dependent regulation of the orphan nuclear receptor small heterodimer partner (SHP) ( ). AMPK activation caused upregulation of SHP gene expression and this in turn, Kim et al., 2008 inhibits PEPCK and G6Pase gene expression. It has been proposed that metformin could regulate the expression of hepatic gluconeogenic genes via both a short-term pathways, involving the protein stabilization or phosphorylation of AMPK-targeted transcription factors and coactivators, such as TORC2 ( ), HNF4 ( , ) and FoxO1 ( ) and a Shaw et al., 2005 α Leclerc et al., 2001 Hong et al., 2003 Barthel et al., 2002 long-term effect exerted via the induction of SHP gene expression ( ) ( ). Lastly, it should be noted that AMPK has Kim et al., 2008 Figure 3 been also involved in the repression of gluconeogenic genes in response to ECGC treatment via a LKB1-independent pathway relying on CaMKK activation through production of ROS ( ). Collins et al., 2007 
Management of glucose homeostasis and dyslipidemia
The growing evidence that AMPK regulates the coordination of anabolic and catabolic metabolic processes represents an attractive therapeutic target for intervention in many conditions of disordered energy balance, including obesity, type 2 diabetes, and the metabolic syndrome ( ). Support for this idea came from treatment with AICAR of various animal models of insulin Winder and Hardie, 1999 in vivo resistance, causing improvement of metabolic disturbances, at least partly by lowering blood glucose levels and increasing insulin sensitivity ( , , , Bergeron et al., 2001 Buhl et al., 2002 Iglesias et al., 2002 Song et al., 2002 Pold et al., 2005 Fiedler et al., 2001 Chronic treatment with AICAR was also shown to reduce plasma TG levels and adiposity in obese animals ( , Bergeron et al., 2001 Buhl et , ) . Furthermore, similar beneficial metabolic effects have been also obtained by direct AMPK activation in the al., 2002 Song et al., 2002 liver by overexpression of AMPK-CA or by the use of the AMPK activator A-769662, leading to decreased plasma glucose, plasma TG levels and adiposity in diabetic, obese and high fat fed mice ( , , ). These results Cool et al., 2006 Foretz et al., 2005 Yang et al., 2008 suggest that direct targeting of the liver is crucial for improving glucose and lipid metabolism, thereby preventing and treating type 2 diabetes. Accordingly, it appears that the major effect of intravenous AICAR infusion in type 2 diabetic patients was on the liver with inhibition of hepatic glucose output and decreased blood glucose levels ( ). However, as liver samples were not collected Boon et al., 2008 in this study, one can only speculate on the role of hepatic AMPK in this therapeutic effect of AICAR. Indeed, inhibition of hepatic glucose output could have resulted from AMPK-independent effects, such as inhibition of fructose-1,6-bisphosphatase by ZMP accumulation in the liver ( ) and see above Furthermore, AICAR administration could also stimulate hepatic fatty acid [ Vincent et al., 1991 ] oxidation and/or inhibit whole body lipolysis, thereby reducing plasma non-esterified fatty acids (NEFA) concentration (Boon et al., 2008 ). Unexpectedly, the effect of AICAR infusion on skeletal muscle glucose uptake was not evident and no changes in AMPK activity were detected in skeletal muscle. Similarly, in another study performed in healthy humans, AMPK activity was not modified in skeletal muscle after AICAR infusion ( ),reinforcing the role of the liver in the action of AICAR. Cuthbertson et al., 2007 Several reports indicate that metformin and TZDs can reduce risk for type 2 diabetes in people with glucose intolerance (Knowler et ). Interestingly, these two drugs have been reported to activate AMPK which is now considered as a new target for the al., 2002 management of insulin-resistant state. Consistent with these data, AMPK now appears to be activated by a multitude of natural products such as polyphenols and traditional Chinese medicine able to reduce blood glucose levels in obese and diabetic animal models ( ) .  table 1 Pathophysiology and management of type 2 diabetes are complex. Increased concentrations of NEFA and inflammatory cytokines (e.g., tumor necrosis factor TNF and interleukin 6 IL-6 ) released by expanded visceral adipose tissue are crucial mechanisms involved in
the alteration of insulin signaling cascade ( ). Adiponectin is another important key of the pathophysiology of type 2 Stumvoll et al., 2005 diabetes. Adiponectin has favourable effects on insulin resistance, hepatic steatosis and inflammation ( ). It is now Kadowaki et al., 2006 well established that circulating levels of adiponectin are decreased in individuals with obesity and insulin resistance, suggesting that its deficiency may have a causal role in the etiopathogenesis of these diseases and their consequences. Thus, adiponectin replacement or restoration of endogenous secretion in humans may represent a promising approach to prevent and/or treat obesity, insulin resistance and the metabolic syndrome. The chronic effects of adiponectin on insulin resistance were investigated by generating adiponectin in vivo transgenic mice. Globular adiponectin transgenic mice showed partial amelioration of insulin resistance and diabetes ( ob/ob Yamauchi et
) and full length adiponectin showed suppression of insulin-mediated endogenous glucose production ( ). al., Yamauchi et al., 2002 Interestingly, it has been shown that metabolic and insulin-sensitizing effects of TZDs are in part mediated through increase in adiponectin availability. Indeed, TZDs metabolic effects are abolished in lipoatrophic mice suggesting that adipose tissue is an essential key of TZDs action ( ). In addition, TZDs can markedly enhance the expression and secretion of adiponectin and Chao et al., 2000 in vitro in vivo through the activation of its promoter and also by blocking the suppressive effect of TNF on the production of adiponectin. Even if the α intracellular adiponectin signaling is not yet completely described, it is clearly demonstrated that adiponectin activates hepatic AMPK (
). In consequence, TZDs probably activate AMPK by an indirect mechanism, through increase of adiponectin levels. Yamauchi et al., 2002 This is suggested by the reduction of AMPK activation by rosiglitazone in adiponectin KO mice ( ). A possible Nawrocki et al., 2006 similar mechanism of action could concern AICAR (but not metformin) which increase the expression of adiponectin in human adipose tissue as TZDs ( ). Lihn et al., 2004 
Management of fatty liver and hepatic fibrosis
Nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disease in western countries, is considered as the hepatic manifestation of the metabolic syndrome ( ). NAFLD is highly associated with obesity and insulin resistance and represent a Angulo, 2002 broad spectrum of liver abnormalities ranging from simple hepatic steatosis (accumulation of TG inside hepatocytes) to a more severe form, nonalcoholic steatohepatitis (NASH), which is associated with hepatocyte damage, chronic inflammation, and fibrosis, and may progress to cirrhosis and liver failure. Studies in humans and various animal models have suggested that efforts to enhance insulin sensitivity might improve fatty liver disease, a situation frequently observed in patients with metabolic syndrome. The efficacy of metformin as a treatment for fatty liver disease has been confirmed in obese, mice, which develop hyperinsulinemia, insulin ob/ob resistance and fatty livers ( ). Recent studies suggest that activation of AMPK accounts for the lipid-lowering effect of Lin et al., 2000 metformin in cultured hepatocytes ( ). Similarly, adiponectin restores insulin sensitivity and decreases hepatic steatosis by Zang et al., 2004 lowering TG content in the liver of obese mice ( , ) . The action of adiponectin is linked to an Xu et al., 2003 Yamauchi et al., 2001 activation of hepatic AMPK, ultimately leading to decreased fatty acid biosynthesis and increased mitochondrial fatty acid oxidation ( ). The role of AMPK has been confirmed by the decrease in liver TG content in lean and obese rodents during Yamauchi et al., 2002 AICAR infusion ( ) and treatment with direct AMPK activator A-769662 ( ). In addition, it has been Bergeron et al., 2001 Cool et al., 2006 recently demonstrated that resveratrol improves insulin sensitivity and protects against lipid accumulation in the liver of diabetic and high-fat fed animals concomitantly with activation of hepatic AMPK ( , ). These effects have been Baur et al., 2006 Shang et al., 2008 correlated to increased mitochondrial number and SIRT1-mediated PCG-1 deacetylation, and decreased expression of lipogenic genes in α the liver. Similarly, the beneficial effect of betaine (trimethylglycine), a naturally occurring metabolite of choline, on high-sucrose diet-induced hepatic steatosis in mice is associated with increased activation of hepatic AMPK ( ). Promising therapeutic Song et al., 2007 effects of betaine supplementation on human NAFLD have been reported in a pilot clinical studies ( ) but the use Abdelmalek et al., 2001 of betaine has been also described earlier in the treatment of alcoholic fatty liver disease (AFLD) ( ). Although, the Barak et al., 1997 underlying causes of NAFLD and AFLD are clearly different, there are similarities in the disturbances of hepatic metabolism. This is supported by reports showing that treatement with adiponectin alleviated alcoholic and non-alcoholic fatty liver disease in mice, partly due to enhanced hepatic fatty acid oxidation and decreased fatty acid synthesis ( ). Interestingly, chronic ethanol ingestion Xu et al., 2003 causes the impairment of AMPK-mediated regulation of fatty acid metabolism and may have an important role in the development of alcoholic fatty liver ( , ) . Activation of AMPK by AICAR or metformin largely blocked the You et al., 2004 Garcia-Villafranca et al., 2008 ability of ethanol to increase levels of SREBP1c protein and expression of SREBP1c-regulated lipogenic enzymes and also appears to protect the liver from fatty changes associated with chronic alcohol use ( , ). Very recently, treatment You et al., Tomita et al., 2005 with resveratrol has been also shown to prevent the development of alcoholic liver steatosis through the SIRT1-AMPK signaling system associated with increased circulating adiponectin levels and enhanced expression of hepatic AdipoR1 and R2 receptors (Ajmo et al., 2008 fibrosis, the molecular mechanisms involved in these conditions are still unclear. Adiponectin levels which have been directly correlated with insulin sensitivity are closely and inversely associated with degree of hepatic steatosis, necroinflammation, and fibrosis in NAFLD (
). Recent studies have demonstrated that in rat HSCs, adiponectin inhibits proliferation, migration, and expression of Targher et al., 2006 fibrogenic genes, and it may induce apoptosis of activated cells ( ). Furthermore, administration of adiponectin Ding et al., 2005 in vivo prevents proliferation of activated HSCs and reduces the development of fibrosis and liver damage during experimental steatohepatitis (Xu , ) . In addition to adiponectin, AICAR and metformin significantly inhibited proliferation and migration of et al., Kamada et al., 2003 human HSCs in a dose-dependent manner ( ). The beneficial effect of these compounds is linked to suppression of Caligiuri et al., 2008 platelet-derived growth factor (PDGF) expression in HSCs and subsequent inhibition of type I procollagen secretion (Caligiuri et al., 2008 , ) . 
Conclusion
Hepatic metabolism is highly sensitive to the variations in nutritional and hormonal signals reflecting changes in whole body energy demands. The AMPK system plays a major role in the regulation of hepatic glucose and lipid metabolism through its acute effect on energy metabolism and long-term effects on gene expression pattern in the liver. Activation of hepatic AMPK causes a switch from anabolic to catabolic state and entails metabolic consequences that are beneficial for diabetic patients, such as inhibition of HGP and restoration of blood glucose levels. AMPK is a key player in regulating energy balance at both cellular and whole-body levels, placing it as an ideal therapeutic target for the treatment of altered energy metabolism that occur in conditions like insulin resistance, type 2 diabetes and the metabolic syndrome. A large number of AMPK activators have been employed with promising results in animal models with obesity or type 2 diabetes and also in preliminary studies with diabetic patients. These encouraging results have provided the rationale for the development of new pharmacological but also nutritional AMPK activators. However, the widespread cellular functions of AMPK make its selective targeting in therapeutics a difficult one, with simultaneous advantageous and deleterious consequences being possible.
One of the major caveats in the use of AMPK activators is their possible role in the regulation of food intake. Stimulation of AMPK expressed in specific nuclei of the hypothalamus has been shown to increase food intake ( ). The ideal AMPK Minokoshi et al., 2004 activators will be administrated by the oral route, will activate AMPK at low concentration and be effective in specific target tissue, such as the liver but not the hypothalamus, and will also have minimal off-target and/or side effects. Finally, it is now becoming apparent that distinct expression patterns of AMPK isoforms exist between rodent and human liver. This finding will have significant implications for the understanding of the physiological role of AMPK complexes across species and for the design of new therapeutic agents targeting human AMPK complexes.
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